ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1881

HLA-DRB1 Rheumatoid Arthritis Susceptibility Amino Acids Define Haplotypes Associated With Radiological Outcome

Sebastien Viatte1, Annie Yarwood2, Buhm Han3,4, Soumya Raychaudhuri3, Deborah P. M. Symmons5, Jane Worthington6,7 and Anne Barton8,9, 1Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 3Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 4Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, 5Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 6Arthritis Research UK Epidemiology Unit, The University of Manchester and Rheumatoid Arthritis Consortium for Immunochip (RACI), International Consortium, United Kingdom, 7Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 8Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 9NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Outcome measures, pathogenesis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Genetics and Genomics of Rheumatic Disease II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rheumatoid arthritis (RA) is a systematic autoimmune disease caused by the interplay between environmental and genetic risk factors. The major genetic determinants of RA susceptibility comprise a group of alleles of the HLA DRB1 gene, which encode a similar amino-acid (aa) motif in the peptide binding groove of the beta chain and are collectively referred to as the shared epitope (SE). Several studies investigated different classifications of HLA-DRB1 alleles and their association with disease susceptibility. Recently, we reported a new classification system based on 3 HLA-DRB1 aa independently associated with RA susceptibility. We demonstrated that HLA-DRB1 haplotypes defined solely by aa at positions 11, 71 and 74 can be hierarchically classified regarding their effect size on RA susceptibility, ranging from risk to protective haplotypes. The impact of this classification on the prediction of radiological outcome in RA has not been studied so far.

Aims: To test whether the RA risk hierarchy within HLA-DRB1 haplotypes also associates with radiological outcome.

Methods: The Norfolk Arthritis Register (NOAR) is a primary care based inception cohort of patients with inflammatory polyarthritis (IP). Radiographs of the hands and feet were performed at baseline, year 1 and year 2 for some patients, and systematically at year 5 for all patients and scored using the Larsen technique. The HLA region of a subset of NOAR patients was densely genotyped using a custom Illumina® Infinium® array (ImmunoChip), imputed and HLA-DRB1 aa at positions 11, 71 and 74 were derived. In order to incorporate multiple records per patient over time and to fit the non-normal distribution of Larsen scores, Generalized Linear Latent and Mixed Modelling (GLLAMM) with discrete random effects and three latent classes was used to assess the association between Larsen score and HLA-DRB1 haplotypes longitudinally.

Results: 1685 NOAR patients had at least one x-ray available and 4-digit HLA-DRB1 typing with a total of 2796 x-rays. Of these, 482 were genotyped on the ImmunoChip platform. HLA-DRB1 haplotypes based on positions 11, 71 and 74 were grouped in 3 haplotype categories, based on their known effect on disease susceptibility (risk, neutral or protective). Preliminary multivariate haplotype group analysis showed a correlation between known effect sizes for susceptibility and effect sizes for severity. The protective group of HLA-DRB1 haplotypes on RA susceptibility (Ser-Lys-Arg or Ser-Glu-Ala at 11, 71, 74, corresponding to HLA-DRB1*03:01, *11:02, *11:03, *13:01, *13:02) is protective for the development of radiological damage as well, independently of the SE.

Conclusion: Susceptibility HLA-DRB1 haplotypes define severity haplotypes as well. Protective HLA-DRB1 haplotypes on radiological severity were also identified. Since the effect size of HLA-haplotypes is likely to outweigh the effect of non-HLA single nucleotide polymorphisms in the prediction of disease outcome, our findings may be relevant in stratifying patients into different risk categories prior to the initiation of treatment.


Disclosure:

S. Viatte,
None;

A. Yarwood,
None;

B. Han,
None;

S. Raychaudhuri,
None;

D. P. M. Symmons,
None;

J. Worthington,
None;

A. Barton,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hla-drb1-rheumatoid-arthritis-susceptibility-amino-acids-define-haplotypes-associated-with-radiological-outcome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology